FibroBiologics, Inc. (FBLG)
0.95
-0.07
(-6.86%)
USD |
NASDAQ |
Oct 23, 16:00
0.9643
+0.01
(+1.51%)
After-Hours: 20:00
FibroBiologics Shareholders Equity (Quarterly) : 4.636M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.636M |
| March 31, 2026 | 2.60M |
| December 31, 2025 | 6.156M |
| September 30, 2025 | 0.125M |
| June 30, 2025 | 0.86M |
| March 31, 2025 | 2.35M |
| December 31, 2024 | 2.735M |
| September 30, 2024 | 2.737M |
| Date | Value |
|---|---|
| June 30, 2024 | -2.387M |
| March 31, 2024 | -3.863M |
| December 31, 2023 | 1.253M |
| September 30, 2023 | 10.54M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | -3.996M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 7.929M |
| Total Liabilities (Quarterly) | 3.293M |
| Debt to Equity Ratio | 0.3154 |
| Current Ratio | 2.644 |
| Net Debt Paydown Yield | 19.62% |